ライフサイエンスコーパス: contrast-enhanced

1 A few days later, she underwent contrast-enhanced (100 mL iohexol, Omnipaque; GE Healthc

2 ced T1-weighted fat-saturated, and (c) axial contrast-enhanced (20 mL gadoteric acid, Dotarem; Guerbe

3 ced T1-weighted fat-saturated, and (c) axial contrast-enhanced (20 mL gadoteric acid, Dotarem; Guerbe

4 ced T1-weighted fat-saturated, and (c) axial contrast-enhanced (20 mL gadoteric acid, Dotarem; Guerbe

5 hree-dimensional fast field-echo T1-weighted contrast-enhanced (7 mL of gadobutrol, Gadavist; Bayer H

6 hree-dimensional fast field-echo T1-weighted contrast-enhanced (7 mL of gadobutrol, Gadavist; Bayer H

7 All patients underwent contrast enhanced abdominal CT.

8 Evaluation with a contrast-enhanced abdominopelvic computed tomography (CT

9 ffect on the results of quantitative dynamic contrast-enhanced analysis of breast tissue at 3 T, whic

10 covery imaging sequences) and multiregional (contrast-enhanced and unenhanced) tumor volumes.

11 t predominantly (in 4/5 patients) within MRI contrast-enhanced areas, although (89)Zr-bevacizumab upt

12 le (FA) mapping were included in the dynamic contrast-enhanced breast MR imaging protocol with a 1.5-

13 hould be considered for quantitative dynamic contrast-enhanced breast MR imaging, even at 1.5 T, to o

14 risk for breast cancer who underwent annual contrast-enhanced breast MRI screening did not exhibit T

15 ute myocardial blood flow (MBF) from dynamic contrast-enhanced cardiac computed tomography acquisitio

16 y rehearsed the procedure step by step using contrast-enhanced cardiac computed tomography and a pati

17 ET exams were recruited to receive a dynamic contrast-enhanced cardiac computed tomography exam.

18 l population, a clinically practical dynamic contrast-enhanced cardiac computed tomography provided u

19 Of the 68 dynamic contrast-enhanced cardiac computed tomography scans, 5 w

20 cardial late gadolinium enhancement (LGE) on contrast-enhanced cardiac magnetic resonance (group A) w

21 on (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MR

22 ture underwent clinical assessment, ECG, and contrast-enhanced cardiovascular magnetic resonance with

23 nts underwent multimodal cardiac assessment: contrast-enhanced cardiovascular magnetic resonance, ech

24 ively and quantitatively by high-resolution, contrast-enhanced carotid MRI at 3T using dedicated surf

25 Gold-standard contrast enhanced computed tomography and magnetic reson

26 ly practice as a better predictive tool than contrast-enhanced computed tomographic scan for therapeu

27 To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identi

28 ental FBV was validated against nanoparticle contrast-enhanced computed tomography (CE-CT) derived pl

29 ic resonance (MR) imaging in comparison with contrast-enhanced computed tomography (CECT) in diagnosi

30 In contrast-enhanced computed tomography (CECT), the change

31 design of multifunctional nanomaterials for contrast-enhanced computed tomography (CT) imaging, X-ra

32 Staging imaging with a contrast-enhanced computed tomography (CT) scan of the c

33 Contrast-enhanced computed tomography (CT) scan revealed

34 We retrospectively analysed contrast-enhanced computed tomography (CT) scans of ches

35 Bladder schistosomiasis was suspected after contrast-enhanced computed tomography and later confirme

36 Four-dimensional contrast-enhanced computed tomography assessed HALT at 3

37 vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention

38 hould be conducted indefinitely with dynamic contrast-enhanced computed tomography or magnetic resona

39 l leisure sports underwent a noncontrast and contrast-enhanced computed tomography scan to assess cor

40 eart technology that incorporates inFAT from contrast-enhanced computed tomography to noninvasively p

41 inFAT distributions were reconstructed from contrast-enhanced computed tomography.

42 to 29 ischemic cardiomyopathy patients with contrast-enhanced computed tomography.

43 entricular tachycardias (VT) identifiable on contrast-enhanced computed tomography.

44 and 2) to compare DP-CBCT with pre-procedure contrast enhanced cross-sectional images in terms of tum

45 rolled to undergo both standard and low-dose contrast enhanced CT scans, which were categorized as no

46 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

47 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

48 Methods: All patients underwent contrast-enhanced CT (ceCT) for TNM staging before (68)G

49 bone lesion assessment by (18)F-FDG PET plus contrast-enhanced CT (ceCT) or BS plus ceCT, for patient

50 Contrast-enhanced CT (CECT) using CA4+ reveals significa

51 ic contrast-enhanced MR imaging (DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinom

52 c, 155 underwent both preoperative ECG-gated contrast-enhanced CT and TEE.

53 etic valve dysfunction and underwent in vivo contrast-enhanced CT angiography, (18)F-fluoride PET, an

54 Patients were followed up with contrast-enhanced CT every 2-4 months.

55 cion of a thrombus, which was confirmed on a contrast-enhanced CT examination.

56 erial propagation can be applied to simulate contrast-enhanced CT examinations.

57 premedication regimen before low-osmolality contrast-enhanced CT for a prior allergic-like or unknow

58 ith corticosteroids beginning 5 hours before contrast-enhanced CT has a breakthrough reaction rate no

59 Figure 4: Axial contrast-enhanced CT image of the abdomen.

60 Figure 2b: (a) Axial and (b) coronal contrast-enhanced CT images of the upper abdomen obtaine

61 Figure 2a: (a) Axial and (b) coronal contrast-enhanced CT images of the upper abdomen obtaine

62 ure 1b: (a) Axial and (b) curved reformatted contrast-enhanced CT images of the upper abdomen.

63 ure 1a: (a) Axial and (b) curved reformatted contrast-enhanced CT images of the upper abdomen.

64 y-Five patients with paired non-contrast and contrast-enhanced CT images were randomly selected from

65 Subtraction maps (contrast-enhanced CT minus precontrast CT) were calculat

66 ocedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis.

67 However, contrast-enhanced CT pulmonary angiography (CTPA) has sh

68 Long-term follow-up by way of a contrast-enhanced CT revealed no recanalization of the t

69 Contrast-enhanced CT revealed partial remission in 5, st

70 A contrast-enhanced CT scan showed a big mass of soft tiss

71 We obtained preoperative, contrast-enhanced CT scans and corresponding pathology r

72 (18)F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo.

73 Contrast-enhanced CT serves as a useful imaging tool for

74 A total of 20 contrast-enhanced CT volume scans were acquired in 5 swi

75 All patients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete per

76 All patients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete per

77 luded in estimating the risk associated with contrast-enhanced CT, may still not fully characterize t

78 Thus, contrast-enhanced CTPA superior over non-contrast_enhanc

79 I protocol mandates the inclusion of dynamic contrast enhanced (DCE) imaging, known for its significa

80 Direct contrast enhanced (DCE) MRI revealed the homogenous dist

81 present a method based on diagnostic dynamic contrast enhanced (DCE) MRI that reflects a continuous r

82 eover, no modern MRI-techniques such Dynamic Contrast Enhanced (DCE) or Diffusion Weighted Imaging (D

83 Dynamic Contrast Enhanced (DCE-)MRI can depict the tumor microen

84 minant pulse sequence and benefit of dynamic contrast-enhanced (DCE) imaging, odds ratios (ORs) were

85 Each MR study included a dynamic contrast-enhanced (DCE)-MRI sequence and a T2-weighted (

86 ygenation-level-dependent (TOLD) and dynamic contrast-enhanced (DCE)-MRI.

87 -4 cm underwent single-energy unenhanced and contrast-enhanced dual-energy computed tomography (CT) o

88 Conclusion A contrast-enhanced dual-energy CT protocol developed by u

89 Conclusion Contrast-enhanced dual-energy CT with material attenuati

90 Predictive and prognostic values of dynamic contrast-enhanced, dynamic susceptibility contrast (DSC)

91 Contrast-enhanced ECG-gated PET-CT permitted localizatio

92 pO(2) ), arterial blood gas, spirometry, and contrast-enhanced echocardiography (CE).

93 ygen to the anaemic fetal heart muscle using contrast-enhanced echocardiography.

94 ng surveillance US allows for prompt dynamic contrast-enhanced evaluation, removing the need for furt

95 2-weighted and DW images between the dynamic contrast-enhanced examination and hepatobiliary phase is

96 % CI: -0.25, 0.48; P = .49), or time between contrast-enhanced examinations (r = -0.06; 95% CI: -0.42

97 45 +/- 0.0110 for girls; P = .88), number of contrast-enhanced examinations (r = 0.13; 95% CI: -0.25,

98 required make ultrasonography preferable to contrast-enhanced fluoroscopy, computed tomography, or m

99 constitutive activation of BR signaling, in contrast, enhanced freezing resistance.

100 tion of renal lesions and differentiation of contrast-enhanced from unenhanced lesions, compared with

101 0.95) for facilitation of differentiation of contrast-enhanced from unenhanced renal lesions.

102 s the clinical feasibility of self-gated non-contrast-enhanced functional lung (SENCEFUL) magnetic re

103 Contrast-enhanced high-resolution CT or (18)F-FDG PET im

104 ancement with centripetal filling on delayed contrast-enhanced images.

105 s tumor vasculature as determined by dynamic contrast enhanced imaging using HSA-Gd(III)DTPA.

106 Intravenous contrast-enhanced imaging is invaluable in diagnosing pa

107 Importantly, this intravenous contrast-enhanced imaging modality can be considered in

108 hese methods enable high-quality noninvasive contrast-enhanced imaging of OCT in living subjects, inc

109 and European health systems with two or more contrast-enhanced imaging studies performed >= 30 days a

110 new single-wavelength photoacoustic dynamic contrast-enhanced imaging technique by employing a stimu

111 histological analysis or resource-intensive, contrast-enhanced imaging techniques.

112 Contrast-enhanced imaging uncovered extrinsic compressio

113 nsional quantitative ultrashort time-to-echo contrast-enhanced imaging was used to reconstruct small,

114 1, 2000, and December 31, 2016, who received contrast-enhanced imaging.

115 entional with diffusion-weighted and dynamic contrast-enhanced imaging.

116 r progression and response to therapy, using contrast-enhanced in vivo imaging.

117 Contrast-enhanced in vivo microCT enabled robust, noninv

118 th a reduction in diagnostic performance for contrast-enhanced lesion characterization.

119 (OR) for diagnostic success in patients with contrast-enhanced lesions was 2.54 ((1.25 to 5.15), p<0.

120 Diagnostic accuracy of contrast enhanced low-dose CT was not inferior to standa

121 investigate the feasibility of using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI),

122 Steady-state contrast enhanced magnetic resonance imaging (SSCE-MRI)

123 Nanoparticle contrast-enhanced magnetic resonance imaging (CE-MRI) ma

124 (BBB) leakage can be measured using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) a

125 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) c

126 yed post-contrast sequence in breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) f

127 In this study, dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) w

128 Tens of millions of contrast-enhanced magnetic resonance imaging (MRI) exams

129 Dynamic contrast-enhanced magnetic resonance imaging (MRI) for t

130 on vessel permeability, assessed by dynamic contrast-enhanced magnetic resonance imaging and (99m)Tc

131 We apply CAM to dissect dynamic contrast-enhanced magnetic resonance imaging data taken

132 patients with malignant glial tumors, using contrast-enhanced magnetic resonance imaging to quantita

133 and regional BBB permeability using dynamic contrast-enhanced magnetic resonance imaging(8-10).

134 ndent magnetic resonance imaging and dynamic contrast-enhanced magnetic resonance imaging) and molecu

135 porcine model of reperfused MI using serial contrast-enhanced magnetic resonance imaging.

136 Based on dynamic contrast-enhanced magnetic resonance lymphangiography an

137 udy had nontraumatic chylothorax and dynamic contrast-enhanced magnetic resonance lymphangiography wa

138 The utility of contrast-enhanced mammography (CEM) and (99m)Tc sestamib

139 nonindex suspicious benign lesions than did contrast-enhanced mammography or molecular breast imagin

140 Conclusion Contrast-enhanced mammography, molecular breast imaging,

141 doxetic acid-(Gd-EOB) enhanced liver MRI and contrast-enhanced MDCT in the detection of liver metasta

142 Here, using contrast enhanced micro-computed tomography, we present,

143 t-specific silicone bifurcations compared to contrast-enhanced micro-computed tomography (uCT), which

144 investigated by histological dissection and contrast-enhanced microCT imaging, as well as measuremen

145 Here we introduce high-resolution contrast-enhanced microfocus computed tomography (CE-CT)

146 supporting clinical translation of said non-contrast-enhanced MR angiograms.

147 Dynamic time-resolved contrast-enhanced MR angiography provides information re

148 Conclusion Mn-PyC3A enables contrast-enhanced MR angiography with comparable contras

149 gs of $1870 and $2068 versus noncontrast and contrast-enhanced MR cholangiopancreatography, respectiv

150 ereafter, the remaining full multiparametric contrast-enhanced MR images were read.

151 only a fraction of the full multiparametric contrast-enhanced MR images, consisting of single-plane

152 was similar to that of full multiparametric contrast-enhanced MR imaging (87.2%, 473 of 542).

153 -pentaacetic acid (Gd-EOB-DTPA) with dynamic contrast-enhanced MR imaging (DCEMRI) and contrast-enhan

154 Full multiparametric contrast-enhanced MR imaging allowed detection of one ad

155 el wall enhancement in the arterial phase at contrast-enhanced MR imaging and (b) parent or guardian

156 of biparametric versus full multiparametric contrast-enhanced MR imaging and between-reader agreemen

157 rwent state-of-the-art, full multiparametric contrast-enhanced MR imaging at 3.0-T including high-spa

158 d pattern analysis of dynamic susceptibility contrast-enhanced MR Imaging for evaluation of arteriove

159 s of this meta-analysis suggest that dynamic contrast-enhanced MR imaging has moderate sensitivity an

160 o those of conventional full multiparametric contrast-enhanced MR imaging protocols.

161 ity-adjusted life-year [QALY] gained), while contrast-enhanced MR imaging was favored in younger adul

162 Contrast-enhanced MR imaging was favored with pretest pr

163 Before biopsy, full diagnostic contrast-enhanced MR imaging was performed that included

164 Image data from dynamic contrast-enhanced MR imaging were extracted and analyzed

165 Conclusion Parameter maps derived at dynamic contrast-enhanced MR imaging with high temporal resoluti

166 , 800, 1000, and 1400 mm(2)/sec, and dynamic contrast-enhanced MR imaging, obtained without endorecta

167 atients with IIH who underwent brain MRI and contrast-enhanced MR venography before measurement of LO

168 radiological scores based on cranial MRI and contrast-enhanced MR venography in patients with idiopat

169 Dynamic contrast enhanced MRI (DCE-MRI) coupled with a pharmacok

170 e multiparametric approach contained dynamic contrast enhanced MRI that measured improved vessel feat

171 ic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) for the detection of osse

172 on and water diffusivity (ADC) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted M

173 laque phenotype in RA patients using Dynamic Contrast-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Posi

174 lung cancers (NSCLC), who underwent dynamic contrast-enhanced MRI (DCE-MRI) before concurrent chemo-

175 Data System (BI-RADS) descriptors of dynamic contrast-enhanced MRI (DCE-MRI).

176 ) within the liver and kidneys using dynamic contrast-enhanced MRI (DCE-MRI).

177 Scores for synovial inflammation at DWI and contrast-enhanced MRI agreed in 37 of 45 participants (8

178 al of this study was to compare the value of contrast-enhanced MRI and O-(2-[(18)F]fluoroethyl)-l-tyr

179 rate the effectiveness of a modified dynamic contrast-enhanced MRI approach we have developed to dete

180 sfer constant and plasma volume from dynamic contrast-enhanced MRI as well as DeltaR(2)* peak and are

181 as indeterminate at ultrasonography, dynamic contrast-enhanced MRI can be useful for classification a

182 GBCAs in 5457 pregnancies, representing one contrast-enhanced MRI examination per 860 pregnancies (0

183 inal MRI constituted 22.3% (n = 1536) of all contrast-enhanced MRI examinations during pregnancy.

184 Most contrast-enhanced MRI examinations were performed in the

185 The results indicate that DWI could replace contrast-enhanced MRI for imaging of synovial inflammati

186 of Ran-SPION-rIgP/cIgY-MAP2 using molecular contrast-enhanced MRI in vivo and validated neuronal upt

187 Contrast-enhanced MRI is typically used to follow treatm

188 nts underwent prone (18)F-FDG PET/CT and 3-T contrast-enhanced MRI of the breast.

189 in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive.

190 Multiphasic contrast-enhanced MRI or CT was obtained before and Brem

191 for studies comparing CT with extracellular contrast-enhanced MRI or gadoxetate-enhanced MRI in adul

192 either gadoxetate-enhanced or extracellular contrast-enhanced MRI over CT.

193 rce of interreader variation for all dynamic contrast-enhanced MRI parameters.

194 Second, DWI was compared with contrast-enhanced MRI regarding detection of synovial in

195 We used dynamic contrast-enhanced MRI to assess the effect of hypertensi

196 DOTA) into the cisterna magna during dynamic contrast-enhanced MRI to quantify glymphatic transport k

197 We used dynamic contrast-enhanced MRI to study 68 ovarian tumors that we

198 days of gestation could be estimated through contrast-enhanced MRI using a long circulating blood-poo

199 articipants; 95% CI: 60%, 90%) with DWI when contrast-enhanced MRI was considered the reference stand

200 Contrast-enhanced MRI was evaluated for technical succes

201 Dynamic, contrast-enhanced MRI was used in fully awake rats to fo

202 1 contained pre- and postcontrast sequences (contrast-enhanced MRI), and data set 2 contained precont

203 About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast age

204 he relative performance of CT, extracellular contrast-enhanced MRI, and gadoxetate-enhanced MRI for d

205 igh-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is li

206 FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and t

207 CT, extracellular contrast-enhanced MRI, or gadoxetate-enhanced MRI could

208 BB by low-intensity pFUS+MB, as evidenced by contrast-enhanced MRI, resulted in an immediate damage-a

209 mphatic influx and efflux rates with dynamic contrast-enhanced MRI, showing that glymphatic transport

210 Conclusion At multiphase contrast-enhanced MRI, substantial necrosis helped ident

211 cted of having JIA and showed agreement with contrast-enhanced MRI.

212 ng antiangiogenic therapy more reliably than contrast-enhanced MRI.

213 -positive skeletal findings were examined by contrast-enhanced MRI.

214 Taken together, our findings suggest dynamic contrast-enhanced-MRI can be used to diagnose specific m

215 lications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDC

216 ullary perfusion and RBF were measured using contrast-enhanced multidetector CT, and renal oxygenatio

217 By contrast, enhanced muscle IL-13 signaling was sufficient

218 Unenhanced and contrast-enhanced nephrographic phase CT was performed.

219 By contrast, enhanced nuclear localization of RPW8.2 by add

220 thout B1 correction were seen in the dynamic contrast-enhanced parameters (including the volume trans

221 in labeling (ASL), as a non-invasive and non-contrast enhanced perfusion imaging method, is an attrac

222 Among the dynamic susceptibility contrast-enhanced perfusion curve features, there were a

223 ssess semiquantitative parameters of dynamic contrast-enhanced perfusion MR imaging (DCE) in differen

224 the ipsilateral hemisphere as visualized by contrast-enhanced perfusion MR scans.

225 dynamic susceptibility contrast and dynamic contrast-enhanced perfusion MRI images we build a classi

226 nanoparticle synthesis to SERRS nanoparticle contrast-enhanced preclinical Raman imaging in animal mo

227 Dynamic contrast-enhanced quantitative first-pass perfusion usin

228 tion in diagnostic performance for depicting contrast-enhanced renal lesions by using VNC compared wi

229 f OFC neurons projecting to the amygdala, by contrast, enhanced reversal performance by destabilizing

230 ngs were abnormal, and the patient underwent contrast-enhanced sacroiliac MRI.

231 Thin contrast- enhanced sections and multiplanar CT and MR sc

232 such as diffusion-weighted imaging, dynamic contrast enhanced sequences, and magnetic resonance spec

233 such as diffusion weighted imaging, dynamic contrast enhanced sequences, and magnetic resonance spec

234 , PET/MR imaging with diffusion-weighted and contrast-enhanced sequences depicted distant (30 of 30 [

235 In none of the 507 images did the contrast-enhanced sequences reveal interval progression

236 reafter, VMI(40keV)) were reconstructed from contrast-enhanced spectral chest CT.

237 Of those 52 patients, 46 were referred for contrast-enhanced spectral mammography and targeted ultr

238 These patients were referred for contrast-enhanced spectral mammography and targeted US a

239 In addition, contrast-enhanced spectral mammography depicted 11 of th

240 52 women who underwent breast MR imaging and contrast-enhanced spectral mammography for newly diagnos

241 Contrast-enhanced spectral mammography had similar sensi

242 Conclusion Contrast-enhanced spectral mammography is potentially as

243 Images from contrast-enhanced spectral mammography were analyzed by

244 st imagers with 2.5 years of experience with contrast-enhanced spectral mammography.

245 io offered by TMRET in combination with dual-contrast enhanced subtraction imaging provides new oppor

246 resonance signals that is coupled with dual-contrast enhanced subtraction imaging.

247 Specifically, we utilize not only contrast-enhanced T1 MRI, but also diffusion tensor imag

248 of new or enlarged lesions detected only on contrast-enhanced T1-weighted images and the assessment

249 and 4 on T2-weighted images and kurtosis on contrast-enhanced T1-weighted images showed a significan

250 .91 with FLAIR, 0.94 with DIR, and 0.99 with contrast-enhanced T1-weighted imaging.

251 ivariate model incorporating T2-weighted and contrast-enhanced T1-weighted kurtosis showed good perfo

252 udy implemented 3-dimensional (3D) isotropic contrast-enhanced T2 fluid-attenuated inversion recovery

253 LSN scores from portal venous phase contrast-enhanced thick-section CT images had significan

254 m) that underwent echocardiography and gated contrast-enhanced thoracic aortic computed tomography or

255 proximal aorta >/=4 cm, who also had a gated contrast-enhanced thoracic computed tomography or magnet

256 erwent conventional MR imaging and a dynamic contrast-enhanced three-dimensional spoiled gradient-ech

257 Using synchrotron X-ray phase contrast-enhanced tomography we show exemplar data with

258 Contrast-enhanced tumor and noncontrast-enhanced T2 FLAI

259 Contrast-enhanced tumor volume, noncontrast-enhanced T2

260 enhanced cardiac magnetic resonance imaging, contrast-enhanced two-dimensional transthoracic echocard

261 Contrast-enhanced uCT imaging of mouse femurs was perfor

262 lastoma multiforme (GBM) with intraoperative contrast-enhanced ultrasonography (US) versus that with

263 with and without PVAT in mice using combined contrast-enhanced ultrasonography and intravital microsc

264 Contrast enhanced ultrasound (CEUS) uses shell-stabilize

265 we introduce three-dimensional (3D) dynamic contrast enhanced ultrasound (DCE-US) perfusion map char

266 = .012), improved microvascular perfusion on contrast-enhanced ultrasound (cortex P = .019, medulla P

267 Dynamic contrast-enhanced ultrasound (DCEUS) and photoacoustic (

268 results illustrate the utility of a combined contrast-enhanced ultrasound method with photoacoustic i

269 We hypothesized that contrast-enhanced ultrasound molecular imaging could det

270 In contrast, contrast-enhanced ultrasound molecular imaging showed in

271 nce of intraplaque neovascularization during contrast-enhanced ultrasound was judged semiquantitative

272 eased microvascular perfusion (determined by contrast-enhanced ultrasound) by 65% in the exercised le

273 maging, glioblastoma contrast enhancement at contrast-enhanced US (regarding location, morphologic fe

274 Contrast-enhanced US also provides dynamic real-time ass

275 undergoing PCNL provided consent to undergo contrast-enhanced US and fluoroscopic nephrostograms on

276 ttern demonstrated a similar distribution in contrast-enhanced US and gadolinium-enhanced T1-weighted

277 Contrast-enhanced US demonstrated ureteral patency in ei

278 t washout of greater than 60 seconds was the contrast-enhanced US feature most predictive of HCC diag

279 The application of contrast-enhanced US immediately following surveillance

280 Thus, contrast-enhanced US is of potential use in the surgical

281 usion Glioblastoma contrast enhancement with contrast-enhanced US is superimposable on that provided

282 r studies confirm these preliminary results, contrast-enhanced US may provide a safer, more convenien

283 Conclusion Contrast-enhanced US nephrostograms are simple to perfor

284 o complications or adverse events related to contrast-enhanced US occurred.

285 The authors believe contrast-enhanced US provides complementary information

286 Contrast-enhanced US results were compared against those

287 ual navigation enabled matching of real-time contrast-enhanced US scans to corresponding coplanar pre

288 pattern differed between the two modalities: Contrast-enhanced US showed enhancement of the entire bu

289 Navigated contrast-enhanced US was performed after intravenous adm

290 dolinium-enhanced T1-weighted MR imaging and contrast-enhanced US was superimposable in all cases wit

291 Nodules assessed with contrast-enhanced US were assigned various CEUS LI-RADS

292 Color Doppler US and contrast-enhanced US were performed to determine the abs

293 For contrast-enhanced US, 1.5 mL of Optison (GE Healthcare,

294 ratio was 5.7 for color Doppler US, 4.3 for contrast-enhanced US, 3.6 for strain elastography, 14.3

295 By combining strain elastography and contrast-enhanced US, a sensitivity of 100% and specific

296 .4% for color Doppler US, 100% and 76.7% for contrast-enhanced US, and 100% and 72.1% for strain elas

297 cysts, with selected indications for MRI and contrast-enhanced US.

298 d 14.3 for strain elastography combined with contrast-enhanced US.

299 ) lesions, which were positive for cancer at contrast-enhanced US.

300 h color Doppler US, strain elastography, and contrast-enhanced US.